Step 8 Semaglutide: Reaching the 2.4 mg Maintenance Dose on Wegovy

The misconception worth clearing up first: step 8 is not a finish line

A common assumption is that reaching 2.4 mg means treatment is complete or that weight loss will now accelerate sharply. Neither is quite right. The maintenance dose is the step where your body is receiving semaglutide at the level studied in the major trials, not a ceiling you push through, but a steady state you sustain. Some people notice continued gradual weight reduction over the following months; others find their weight plateaus, which is a normal physiological response rather than a failure of the medicine.

It also helps to understand what semaglutide is doing at this dose. As a GLP-1 receptor agonist, it works by mimicking a gut hormone that signals fullness, slows gastric emptying and helps regulate appetite. By step 8 that mechanism is operating at its licensed maximum. The NHS medicines information for semaglutide outlines how the drug works and what to expect, and it is worth reading alongside any information your prescriber provides.

For people who have found the earlier steps manageable, 2.4 mg often feels similar to 1.7 mg with continued appetite suppression. For others, side effects that were mild lower down the schedule can resurface briefly after this final dose increase. That is expected, and usually settles within a couple of weeks.

The titration path that leads to step 8 on Wegovy

The full semaglutide schedule runs: 0.25 mg → 0.5 mg → 1.0 mg → 1.7 mg → 2.4 mg, with each step lasting around four weeks as directed by your prescriber. You can read about the earlier stages of the journey on our semaglutide step guide, or look at specific steps if you have questions about a particular point in the schedule, such as step 3 or step 6.

The reason the schedule exists at all is tolerability. GLP-1 medicines produce gastrointestinal effects (nausea, loose stools, indigestion) that are most noticeable when the dose first increases. A slow titration lets the body adapt. Rushing through steps, or jumping straight to 2.4 mg, would almost certainly mean worse side effects and would be clinically inappropriate. Your prescriber sets the pace based on how you are getting on, not a calendar.

One practical point many patients raise: how do you keep track of where you are in the schedule? Most people find a simple note on their phone or on a magnet stuck to the fridge door works well. The pen lives in the fridge anyway, a quick note next to it saves confusion at the seven-month mark when the steps start to blur.

Side effects to be aware of at step 8 specifically

The side-effect profile at 2.4 mg is broadly the same as at earlier doses (predominantly gastrointestinal) but a small number of people find the final step brings a fresh wave of nausea or loose stools that had largely settled. This is well documented in the trial data and does not usually mean you need to stop. Eating smaller portions, avoiding high-fat meals and staying well hydrated are the practical measures most prescribers suggest.

One serious side effect that warrants urgent attention at any dose is severe stomach pain that radiates to the back, with or without vomiting. This can be a sign of acute pancreatitis, and the MHRA issued specific guidance on this risk for GLP-1 medicines in early 2026. Do not wait to speak to a doctor if this happens. You can also report any suspected side effect through the MHRA's Yellow Card scheme.

For a fuller overview of what semaglutide is and how it fits into weight management, our Wegovy information page covers the licensed indication, eligibility and what the clinical programme found. If you are weighing up whether Wegovy is the right treatment for your situation, the broader semaglutide guide sets out the context clearly.

Continuing beyond step 8: what happens next

NICE's recommendation for semaglutide (TA875) stipulates use for a maximum of two years within a specialist weight management service on the NHS. In the private setting, continuation is a clinical decision made with your prescriber, reviewed at each repeat order. There is no automatic renewal; every repeat goes through clinical re-review to confirm the medicine remains appropriate.

A newer option worth knowing about is the 7.2 mg semaglutide pen approved by the MHRA in April 2026, a higher maintenance dose for eligible adults with a BMI of 30 or above. Whether that is an appropriate next step is a conversation for your prescriber, not something to decide independently.

If you are thinking about the cost side of treatment, our Wegovy cost guide explains what private treatment typically includes and why the headline price varies between providers. And if you are ready to talk through your own situation, you can speak to our prescribers through a free consultation, reviewed the same day by a GPhC-registered Independent Prescriber, with no algorithm in the middle.